浙江大学外科研究所副所长，浙江大学医学院附属邵逸夫医院普外科副主任、肝胆胰外科主任、外科教研室主任、教授、主任医师、医学博士、博士生导师。 长期从事肝胆胰恶性肿瘤及消化系统疾病的基础研究和临床诊治工作。至今已以第一或通讯作者发表论文60余篇，其中SCI收录论文40余篇，主持国家级及省部重点科研项目十余项，其中已五次获国家自然科学基金资助。作为主要成员曾获国家科技进步奖、国家发明奖等奖项；作为主持人曾获浙江省科技进步二等奖、浙江省科技进步三等奖等奖项。 研究项目 国家自然科学基金面上项目，干扰素-γ诱导RFXAP调控胰腺癌染色体不稳定性的作用及其机制，2018/01-2021/12，在研，主持。 国家自然科学基金面上项目，81971479，外泌体调控T细胞未折叠蛋白反应导致免疫逃逸的机制研究，2020/01-2023/12，在研，主持。 浙江省重点研发项目，2019C03048，高发恶性肿瘤诊治新技术研究-基于染色体不稳定性分型的胰腺癌精准免疫治疗临床研究，2019.01-2022.12，在研，主持。 国家自然科学基金面上项目，胰腺癌外泌体(exosome)诱导的RFXAP基因沉默在胰腺癌早期转移发生中的作用及机制，2016/01-2019/12，已结题，主持。 国家自然科学基金面上项目，胰腺癌诱导DC分化和DC-SIGN表达的microRNA调控机制研究，2013/01-2016/12，已结题，主持。 国家自然科学基金面上项目，rMICA 在肝移植免疫中的作用及其机理，2009/01-2011/12，30万元，已结题，主持。 国家卫生和计划生育委员会省部共建项目，基于血清外泌体的胰腺癌精准诊断研究，2018/01-2021/12，在研，主持。 国家卫生和计划生育委员会科研基金，基于exosome的DC/CIK细胞诱导及其治疗胰腺癌的实验研究，2013/06-2015/12，已结题，主持。 浙江省科技厅重大科技专项项目，树突状细胞通过DC-SIGN介导肝脏胆管细胞癌免疫识别和免疫逃逸的研究及应用，2011/01-2014/08，已结题，主持。 获得学术奖励 胆胰恶性肿瘤的早期诊断与治疗，浙江省人民政府，科技进步，省部二等奖，2015.1.2 肝尾状叶切除手术策略与方法的研究。国家科学技术进步奖一等奖。2008.1.25

肝胆胰恶性肿瘤发生及治疗 肝胆胰疾病 肿瘤免疫逃逸

担任美国外科学院（FACS）委员、亚洲内镜与腹腔镜外科医师协会（ELSA）委员、中华医学会外科学分会外科手术学组委员、浙江省医师协会微创外科专业委员会候任主任委员、浙江省医学会微创外科学分会副主任委员、浙江省抗癌协会肿瘤微创诊治专业委员会副主任委员、浙江省医学会外科学分会常务委员。

一、已发表SCI论文 1. Elevated expression of exosomal microRNA‑21 as a potential biomarker for the early diagnosis of pancreatic cancer using a tethered cationic lipoplex nanoparticle biochip. Xiaofan Pu, Guoping Ding, Mingjie Wu, Senhao Zhou, Shengnan Jia, Liping Cao. Oncology Letters 19: 2062-2070, 2020. 2. Interferon gamma inhibits CXCL8-CXCR2 axis mediated tumor-associated macrophages tumor trafficking and enhances anti-PD1 efficacy in pancreatic cancer. Zhang M, Huang L, Ding G, Huang H, Cao G, Sun X, Lou N, Wei Q Shen T, Xu X, Cao L, Yan Q. Journal for ImmunoTherapy of Cancer. 2020 Feb;8(1). pii: e000308. doi: 10.1136/jitc-2019-000308. 3. Pancreatic Cancer-Derived Exosomes Induce Apoptosis of T Lymphocytes Through the p38 MAPK-mediated Endoplasmic Reticulum Stress. Tao Shen , Zihang Huang, Chengfei Shi, Xiaofan Pu , Xiaodong Xu , Zhengrong Wu , Guoping Ding , Liping Cao. FASEB J. 2020 Jun;34(6):8442-8458. 4. BxPC-3-Derived Small Extracellular Vesicles Induce FOXP3+ Treg through ATM-AMPK-Sirtuins-Mediated FOXOs Nuclear Translocations. Tao Shen, Shengnan Jia, Guoping Ding, Dongnan Ping, Liangjing Zhou, Senhao Zhou, Liping Cao. iScience. 2020 Aug 21;23(8):101431. doi: 10.1016/j.isci.2020.101431. 5. Fisetin inhibits proliferation of pancreatic adenocarcinoma by inducing DNA damage via RFXAP/KDM4A-dependent histone H3K36 demethylation. Guoping Ding, Xiaodong Xu, Dan Li, Yuhao Chen, Weimin Wang, Dongnan Ping, Shengnan Jia and Liping Cao. Cell Death and Disease (2020) 11:893. 6. Fisetin induces autophagy in pancreatic cancer cells via endoplasmic reticulum stress- and mitochondrial stress-dependent pathways. Jia S, Xu X, Zhou S, Chen Y, Ding G, Cao L. Cell Death and Disease. 2019 Feb 13;10(2):142. doi: 10.1038/s41419-019-1366-y. 7. The distinct role of CD73 in the progression of pancreatic cancer. Liangjing Zhou, Shengnan Jia, Yan Chen, Weiming Wang, Zhengrong Wu, Weihua Yu, Mingjie Zhang, Guoping Ding, Liping Cao. Journal of Molecular Medicine. 2019 Mar 29. doi: 10.1007/s00109-018-01742-0. 97 (6), 803-815 Jun 2019. 8. Expression of DEK in pancreatic cancer and its correlation with clinicopathological features and prognosis. Ting Zhao, Bijun Qiu, Senhao Zhou, Guoping Ding, Liping Cao, Zhengrong Wu. Journal of Cancer. 2019; 10(4): 911–917. 9. IFN-γ down-regulates the PD-1 expression and assist nivolumab in PD-1-blockade effect on CD8+ T-lymphocytes in pancreatic cancer. Guoping Ding, Tao Shen, Yan Chen, Mingjie Zhang, Zhengrong Wu and Liping Cao. BMC Cancer (2019) 19:1053. 10. Silencing Of hsa_circ_0008450 Represses Hepatocellular Ca rcinoma Progression Through Regulation Of microRNA-214-3p/EZH2 Axis. Tianyu Lin, Yi Dai, Xinli Guo, Wenchao Chen, Jiangang Zhao, Liping Cao, Zhengrong Wu. Cancer Management and Research 2019:11 9133–9143. 11. Down-regulation of miR-30a-5p is Associated with Poor Prognosis and Promotes Chemoresistance of Gemcitabine in Pancreatic Ductal Adenocarcinoma. Liangjing Zhou, Shengnan Jia, Guoping Ding, Mingjie Zhang, Weihua Yu, Zhengrong Wu, Liping Cao. Journal of Cancer 2019, Vol. 10 5031-5040. 12. Utility of the Surgical Apgar Score in pancreatic cancer and modification. Guoping Ding , Liangjing Zhou, Wenchao Chen, Zhengrong Wu, Tao Shen, Liping Cao. Laparoscopic, Endoscopic and Robotic Surgery 2 (2019) 89-93. 13. Down-expression of CD36 in pancreatic adenocarcinoma and its correlation with clinicopathological features and prognosis. Jia S, Zhou L, Shen T, Zhou S, Ding G, Cao L. J Cancer. 2018;9(3):578-583. 14. High Expression of P38α and Preoperative Carbohydrate Antigen 19-9 Indicate Poor Prognosis in Patients with Pancreatic Ductal Adenocarcinoma. Chen J, Zhao T, Jia S, Zhou S, Zhou L, Wang S, Ding G, Jiang G, Cao L. J Cancer. 2018;9(4):650-659 . 15. Integrated Analysis of Long Non-Coding RNA and mRNA Expression Profile in Pancreatic Cancer Derived Exosomes Treated Dendritic Cells by Microarray Analysis. J Cancer. Jionghuang Chen, Shaowen Wang, Shengnan Jia, Guoping Ding, Guixing Jiang and Liping Cao. 2018;9(1):21-31. 16. A novel scoring system to analyze combined effect of lifestyle factors on pancreatic cancer risk: a retrospective case-control study. Pang T, Ding G, Wu Z, Jiang G, Yang Y, Zhang X, Cao L*. 10 May 2017. 17. Prognostic value of programmed cell death protein 1 expression on CD8+ T lymphocytes in pancreatic cancer, Shen T, Zhou L, Shen H, Shi C, Jia S, Ding G, Cao L*. Sciencific reports,2017:7:7848. 18. Overexpressions of miR-212 are associated with poor prognosis of patients with Pancreatic Ductal Adenocarcinoma. Wu Z, Zhou L, Ding G, Cao L*. Cancer Biomark. 18(2017)35-39. DOI: 10.3233/CBM-160671. 19. Cholangiocarcinoma-derived exosomes inhibit the antitumor activity of cytokine-induced killer cells by down-regulating the secretion of tumor necrosis factor-α and perforin. Chen J, Xiang J, Ding G, Cao L*. J Zhejiang Univ-Sci B. 2016;17(7):537-544.